    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                       	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - ONDANSETRON - ondansetron hydrochloride  injection, solution  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "ONDANSETRON - ondansetron hydrochloride  injection, solution <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">ONDANSETRON - ondansetron hydrochloride  injection, solution <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AONDANSETRON%20%2D%20Ondansetron%20Hydrochloride%20Injection%2C%20Solution%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dd89017aa%2Db8c3%2D4fd2%2D8e68%2D44e2cfd6f290%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=ond03-0009-06.jpg&setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=ond03-0009-06.jpg&setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" src="image.cfm?type=img&name=ond03-0009-06.jpg&setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                												                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Ondansetron%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=Ondansetron" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=Ondansetron" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Ondansetron[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Ondansetron/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Ondansetron/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Ondansetron/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Ondansetron[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00481&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    76045-103-20                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>BD Rx Inc. </li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">Abbreviated New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	01/15                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&amp;type=pdf&amp;name=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&amp;type=zip&amp;name=ONDANSETRON">XML</a>                                                    </li>                                                                                                                                                            <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use Ondansetron Injection safely and effectively. See full prescribing information for Ondansetron Injection.   <br />ONDANSETRON INJECTION USP, for intravenous use   <br />Initial U.S. Approval: 1991   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <table width="100%">      <colgroup>      <col align="left" width="50.000%" />       <col align="left" width="50.000%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left" valign="top">Warnings and Precautions, Serotonin Syndrome (<a href="#s19">5.3</a>) </td>       <td align="right" valign="top">09/2014 </td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">Ondansetron Injection is a 5-HT<span class="Sub">3</span> receptor antagonist indicated: </p>     <ul class="Disc">      <li>Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. (<a href="#s3">1.1</a>) </li>      <li>Prevention of postoperative nausea and/or vomiting. (<a href="#s4">1.2</a>) </li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <p class="Highlighta">Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (<a href="#s6">2.1</a>): </p>     <ul class="Disc">      <li>Adults and Pediatric patients (6 months to 18 years): Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. The first dose should be administered 30 minutes before the start of chemotherapy. Subsequent doses are administered 4 and 8 hours after the first dose. </li>     </ul>     <p class="Highlighta">Prevention of postoperative nausea and/or vomiting (<a href="#s9">2.2</a>): </p>     <table width="100%">      <colgroup>      <col align="left" width="25.500%" />       <col align="left" width="23.775%" />       <col align="left" width="23.600%" />       <col align="left" width="27.125%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> <br /> <span class="Bold">Population</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"> <br /> <span class="Bold">Age</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Ondansetron Injection Dosage</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Intravenous Infusion Rate</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">Adults </td>       <td class="Botrule Rrule" align="center" valign="top">&gt; 12 yrs </td>       <td class="Botrule Rrule" align="center" valign="top">4 mg x 1 </td>       <td class="Botrule Rrule" align="center" valign="top">over 2 - 5 min </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">Pediatrics<br />(&gt; 40 kg) </td>       <td class="Botrule Rrule" align="center" valign="top">1 mo. – 12 yrs </td>       <td class="Botrule Rrule" align="center" valign="top">4 mg x 1 </td>       <td class="Botrule Rrule" align="center" valign="top">over 2 - 5 min </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">Pediatrics<br />(≤ 40 kg) </td>       <td class="Botrule Rrule" align="center" valign="top">1 mo. – 12 yrs </td>       <td class="Botrule Rrule" align="center" valign="top">0.1 mg/kg x 1 </td>       <td class="Botrule Rrule" align="center" valign="top">over 2 - 5 min </td>       </tr>      </tbody>     </table>     <ul class="Disc">      <li>In patients with severe hepatic impairment, a total daily dose of 8 mg should not be exceeded. (<a href="#s13">2.4</a>) </li>     </ul>    </div>    <div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Ondansetron Injection (2 mg/mL): 2 mL Prefilled disposable single-use syringe (<a href="#s14">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disc">      <li>Patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. (<a href="#s15">4</a>) </li>      <li>Concomitant use of apomorphine. (<a href="#s15">4</a>) </li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li>Hypersensitivity reactions including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT<span class="Sub">3</span> receptor antagonists. (<a href="#s17">5.1</a>) </li>      <li>QT prolongation occurs in a dose-dependent manner. Cases of Torsade de Pointes have been reported. Avoid Ondansetron in patients with congenital long QT syndrome. (<a href="#s18">5.2</a>) </li>      <li>Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (<a href="#s19">5.3</a>) </li>      <li>Use in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distention. (<a href="#s20">5.4</a>)(<a href="#s21">5.5</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Chemotherapy-Induced Nausea and Vomiting – </p>     <ul class="Disc">      <li>The most common adverse reactions (≥ 7%) in adults are diarrhea, headache, and fever. (<a href="#s23">6.1</a>) </li>     </ul>     <p class="Highlighta">Postoperative Nausea and Vomiting – </p>     <ul class="Disc">      <li>The most common adverse reaction (≥ 10%) which occurs at a higher frequency compared to placebo in adults is headache. (<a href="#s23">6.1</a>) </li>      <li>The most common adverse reaction (≥ 2%) which occurs at a higher frequency compared to placebo in pediatric patients 1 to 24 months of age is diarrhea. (<a href="#s23">6.1</a>) </li>     </ul>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact BD Rx at 1-866-943-8534 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>    </div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li>Apomorphine – profound hypotension and loss of consciousness.<br />Concomitant use with ondansetron is contraindicated. (<a href="#s30">7.2</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>   <p class="HighlightsRevision">Revised: 9/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy </a> </h2>   <h2> <a href="#section-1.2" class="toc">1.2 Prevention of Postoperative Nausea and Vomiting </a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Chemotherapy </a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Prevention of Postoperative Nausea and Vomiting </a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Stability and Handling </a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Dosage Adjustment for Patients with Impaired Hepatic Function </a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS </a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Hypersensitivity Reactions </a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 QT Prolongation </a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Serotonin Syndrome </a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Masking of Progressive Ileus and Gastric Distension </a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Effect on Peristalsis </a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS </a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS </a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Drugs Affecting Cytochrome P-450 Enzymes </a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Apomorphine </a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Phenytoin, Carbamazepine, and Rifampin </a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Tramadol </a> </h2>   <h2> <a href="#section-7.5" class="toc">7.5 Serotonergic Drugs </a> </h2>   <h2> <a href="#section-7.6" class="toc">7.6 Chemotherapy </a> </h2>   <h2> <a href="#section-7.7" class="toc">7.7 Temazepam </a> </h2>   <h2> <a href="#section-7.8" class="toc">7.8 Alfentanil and Atracurium </a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy </a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers </a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use </a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use </a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Hepatic Impairment </a> </h2>   <h2> <a href="#section-8.6" class="toc">8.7 Renal Impairment </a> </h2>   <h1> <a href="#section-9" class="toc">9 DRUG ABUSE AND DEPENDENCE </a> </h1>   <h1> <a href="#section-10" class="toc">10 OVERDOSAGE </a> </h1>   <h1> <a href="#section-11" class="toc">11 DESCRIPTION </a> </h1>   <h1> <a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY </a> </h1>   <h2> <a href="#section-12.1" class="toc">12.1 Mechanism of Action </a> </h2>   <h2> <a href="#section-12.2" class="toc">12.2 Pharmacodynamics </a> </h2>   <h2> <a href="#section-12.3" class="toc">12.3 Pharmacokinetics </a> </h2>   <h1> <a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY </a> </h1>   <h2> <a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a> </h2>   <h1> <a href="#section-14" class="toc">14 CLINICAL STUDIES </a> </h1>   <h2> <a href="#section-14.1" class="toc">14.1 Chemotherapy-Induced Nausea and Vomiting </a> </h2>   <h2> <a href="#section-14.2" class="toc">14.2 Prevention of Postoperative Nausea and/or Vomiting </a> </h2>   <h2> <a href="#section-14.3" class="toc">14.3 Prevention of Further Postoperative Nausea and Vomiting </a> </h2>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a> </h1>   <h1> <a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION </a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="s2"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s3"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy </h2>    <p class="First"> Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin <span class="Italics">[see Clinical Studies (<a href="#s62">14.1</a>)]</span>. </p>    <p> Ondansetron is approved for patients aged 6 months and older. </p>    <div class="scrollingtable">    <table width="100%">      <colgroup>      <col width="100.000%" />      </colgroup>     <tbody class="Headless">       <tr class="First Last">        <td class="Botrule Lrule Rrule Toprule">CAUTION: THIS 4 MG/2 ML SINGLE DOSE PREFILLED SYRINGE IS NOT FOR USE IN PEDIATRIC PATIENTS LESS THAN 40 KG. DILUTION IS REQUIRED PRIOR TO ADMINISTRATION FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING. </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s4"></a>   <a name="section-1.2"></a>    <p></p>    <h2>1.2 Prevention of Postoperative Nausea and Vomiting </h2>    <p class="First"> Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes <span class="Italics">[see Clinical Studies (<a href="#s71">14.3</a>)]</span>. </p>    <p> Ondansetron is approved for patients aged 1 month and older. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="s5"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s6"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Chemotherapy </h2>    <p class="First"> Ondansetron Injection should be diluted in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection before administration. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s7"></a>    <a name="section-2.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Adults:</span> The recommended adult intravenous dosage of Ondansetron is three 0.15-mg/kg doses up to a maximum of 16 mg per dose <span class="Italics">[see Clinical Pharmacology (<a href="#s49">12.2</a>)]</span>. The first dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. Subsequent doses (0.15 mg/kg up to a maximum of 16 mg per dose) are administered 4 and 8 hours after the first dose of Ondansetron. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s8"></a>    <a name="section-2.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics:</span> For pediatric patients 6 months through 18 years of age, the intravenous dosage of Ondansetron is three 0.15-mg/kg doses up to a maximum of 16 mg per dose <span class="Italics">[see Clinical Studies (<a href="#s62">14.1</a>), and Clinical Pharmacology (<a href="#s49">12.2</a>, and <a href="#s50">12.3</a>)]</span>. The first dose is to be administered 30 minutes before the start of moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg up to a maximum of 16 mg per dose) are administered 4 and 8 hours after the first dose of Ondansetron. The drug should be infused intravenously over 15 minutes. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s9"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Prevention of Postoperative Nausea and Vomiting </h2>    <p class="First"> Ondansetron Injection should not be mixed with solutions for which physical and chemical compatibility have not been established. In particular, this applies to alkaline solutions as a precipitate may form. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s10"></a>    <a name="section-2.2.1"></a>     <p></p>     <p class="First"> <span class="Underline">Adults</span>: The recommended adult intravenous dosage of Ondansetron is 4 mg <span class="Italics">undiluted</span> administered intravenously in not less than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring within 2 hours after surgery. Alternatively, 4 mg <span class="Italics">undiluted</span> may be administered intramuscularly as a single injection for adults. While recommended as a fixed dose for patients weighing more than 40 kg, few patients above 80 kg have been studied. In patients who do not achieve adequate control of postoperative nausea and vomiting following a single, prophylactic, preinduction, intravenous dose of ondansetron 4 mg, administration of a second intravenous dose of 4 mg ondansetron postoperatively does not provide additional control of nausea and vomiting. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s11"></a>    <a name="section-2.2.2"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics</span>: For pediatric patients 1 month through 12 years of age, the dosage is a single 0.1-mg/kg dose for patients weighing 40 kg or less, or a single 4-mg dose for patients weighing more than 40 kg. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes immediately prior to or following anesthesia induction, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring shortly after surgery. Prevention of further nausea and vomiting was only studied in patients who had not received prophylactic Ondansetron. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s12"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Stability and Handling </h2>    <p class="First"> After dilution, do not use beyond 24 hours. Although Ondansetron Injection, USP is chemically and physically stable when diluted as recommended, sterile precautions should be observed because diluents generally do not contain preservative. </p>    <p> Ondansetron Injection, USP is stable at room temperature under normal lighting conditions for 48 hours after dilution with the following intravenous fluids: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, and 3% Sodium Chloride Injection. </p>    <p> <span class="Italics">Note:</span> Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit. </p>    <div class="scrollingtable">    <table width="100%">      <colgroup>      <col width="100.000%" />      </colgroup>     <tbody class="Headless">       <tr class="First Last">        <td class="Botrule Lrule Rrule Toprule">CAUTION: THIS 4 MG/2 ML SINGLE DOSE PREFILLED SYRINGE IS NOT FOR USE IN PEDIATRIC PATIENTS LESS THAN 40 KG. DILUTION IS REQUIRED PRIOR TO ADMINISTRATION FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING. </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s13"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Dosage Adjustment for Patients with Impaired Hepatic Function </h2>    <p class="First"> In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. There is no experience beyond first-day administration of ondansetron in these patients <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="s14"></a>  <a name="section-3"></a>   <p></p>    <p class="First"> Ondansetron Injection, USP 2 mg/mL is a clear, colorless, nonpyrogenic, sterile solution available as a 2 mL Prefilled disposable single-use syringe. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="s15"></a>  <a name="section-4"></a>   <p></p>    <p class="First"> Ondansetron Injection, USP is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron. <span class="Italics">[See Adverse Reactions (<a href="#s27">6.2</a>)].</span> </p>   <p> The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="s16"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s17"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Hypersensitivity Reactions </h2>    <p class="First"> Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT<span class="Sub">3</span> receptor antagonists. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s18"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 QT Prolongation </h2>    <p class="First"> Ondansetron prolongs the QT interval in a dose-dependent manner <span class="Italics">[see Clinical Pharmacology (<a href="#s49">12.2</a>)]</span>. In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid Ondansetron in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking other medicinal products that lead to QT prolongation. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s19"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Serotonin Syndrome </h2>    <p class="First">The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of Ondansetron alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. </p>    <p>Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Ondansetron and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Ondansetron is used concomitantly with other serotonergic drugs [see Drug Interactions (<a href="#s33">7.5</a>), Overdosage (<a href="#s45">10</a>), Patient Counseling Information (<a href="#s78">17</a>)]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s20"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Masking of Progressive Ileus and Gastric Distension </h2>    <p class="First"> The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and gastric distention. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s21"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Effect on Peristalsis </h2>    <p class="First">Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="s22"></a>  <a name="section-6"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s23"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience </h2>    <p class="First"> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </p>    <p> The following adverse reactions have been reported in clinical trials of adult patients treated with ondansetron, the active ingredient of intravenous Ondansetron across a range of dosages. A causal relationship to therapy with Ondansetron was unclear in many cases. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s24"></a>    <a name="section-6.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Chemotherapy-Induced Nausea and Vomiting:</span> </p>     <a name="t1"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 1. Adverse Reactions Reported in &gt; 5% of Adult Patients Who Received Ondansetron at a Dosage of Three 0.15-mg/kg Doses </span>       </caption>       <colgroup>       <col align="left" width="24.981%" />        <col align="left" width="24.981%" />        <col align="left" width="25.006%" />        <col align="left" width="25.031%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"> <br /> <br /> <br /> <br />Adverse Reaction </td>        <td class="Botrule Rrule Toprule" align="left" colspan="3" valign="top">Number of Adult Patients with Reaction </td>        </tr>        <tr>         <td class="Botrule Rrule" align="center" valign="top">Ondansetron Injection<br />0.15 mg/kg x 3<br />n = 419 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br />Metoclopramide<br />n = 156 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br />Placebo<br />n = 34 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Diarrhea </td>        <td class="Botrule Rrule" align="center" valign="top">16% </td>        <td class="Botrule Rrule" align="center" valign="top">44% </td>        <td class="Botrule Rrule" align="center" valign="top">18% </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Headache </td>        <td class="Botrule Rrule" align="center" valign="top">17% </td>        <td class="Botrule Rrule" align="center" valign="top">7% </td>        <td class="Botrule Rrule" align="center" valign="top">15% </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Fever </td>        <td class="Botrule Rrule" align="center" valign="top">8% </td>        <td class="Botrule Rrule" align="center" valign="top">5% </td>        <td class="Botrule Rrule" align="center" valign="top">3% </td>        </tr>       </tbody>      </table>    </div>     <p> <span class="Italics">Cardiovascular:</span> Rare cases of angina (chest pain), electrocardiographic alterations, hypotension, and tachycardia have been reported. </p>     <p> <span class="Italics">Gastrointestinal:</span> Constipation has been reported in 11% of chemotherapy patients receiving multiday ondansetron. </p>     <p> <span class="Italics">Hepatic:</span> In comparative trials in cisplatin chemotherapy patients with normal baseline values of aspartate transaminase (AST) and alanine transaminase (ALT), these enzymes have been reported to exceed twice the upper limit of normal in approximately 5% of patients. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. </p>     <p> <span class="Italics">Integumentary:</span> Rash has occurred in approximately 1% of patients receiving ondansetron. </p>     <p> <span class="Italics">Neurological:</span> There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving Ondansetron injection, and rare cases of grand mal seizure. </p>     <p> <span class="Italics">Other:</span> Rare cases of hypokalemia have been reported. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s25"></a>    <a name="section-6.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Postoperative Nausea and Vomiting:</span> The adverse reactions in <a href="#t2">Table 2</a> have been reported in ≥ 2% of adults receiving ondansetron at a dosage of 4 mg intravenous over 2 to 5 minutes in clinical trials. </p>     <a name="t2"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 2. Adverse Reactions Reported in ≥ 2% (and with Greater Frequency than the Placebo Group) of Adult Patients Receiving Ondansetron at a Dosage of 4 mg Intravenous over 2 to 5 Minutes </span>       </caption>       <colgroup>       <col align="left" width="33.333%" />        <col align="left" width="33.333%" />        <col align="left" width="33.333%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">a</span>Adverse Reactions: Rates of these reactions were not significantly different in the ondansetron and placebo groups </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">b</span>Patients were receiving multiple concomitant perioperative and postoperative medications </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> <br /> <br />Adverse Reaction<span class="Sup">a,b</span></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron Injection<br />4 mg Intravenous<br />n = 547 patients </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br />Placebo<br />n = 547 patients </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Headache </td>        <td class="Botrule Rrule" align="center" valign="top">92 (17%) </td>        <td class="Botrule Rrule" align="center" valign="top">77 (14%) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Drowsiness/sedation </td>        <td class="Botrule Rrule" align="center" valign="top">44 (8%) </td>        <td class="Botrule Rrule" align="center" valign="top">37 (7%) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Injection site reaction </td>        <td class="Botrule Rrule" align="center" valign="top">21 (4%) </td>        <td class="Botrule Rrule" align="center" valign="top">18 (3%) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Fever </td>        <td class="Botrule Rrule" align="center" valign="top">10 (2%) </td>        <td class="Botrule Rrule" align="center" valign="top">6 (1%) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Cold sensation </td>        <td class="Botrule Rrule" align="center" valign="top">9 (2%) </td>        <td class="Botrule Rrule" align="center" valign="top">8 (1%) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Pruritus </td>        <td class="Botrule Rrule" align="center" valign="top">9 (2%) </td>        <td class="Botrule Rrule" align="center" valign="top">3 (&lt; 1%) </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Paresthesia </td>        <td class="Botrule Rrule" align="center" valign="top">9 (2%) </td>        <td class="Botrule Rrule" align="center" valign="top">2 (&lt; 1%) </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s26"></a>    <a name="section-6.1.3"></a>     <p></p>     <p class="First"> <span class="Italics">Pediatric Use:</span> Rates of adverse reactions were similar in both the ondansetron and placebo groups in pediatric patients receiving ondansetron (a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric patients weighing more than 40 kg) administered intravenously over at least 30 seconds. Diarrhea was seen more frequently in patients taking Ondansetron (2%) compared to placebo (&lt;1%) in the 1 month to 24 month age group. These patients were receiving multiple concomitant perioperative and postoperative medications. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s27"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Postmarketing Experience </h2>    <p class="First"> The following adverse reactions have been identified during post-approval use of ondansetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron. </p>    <p> <span class="Underline">Cardiovascular</span>: Arrhythmias (including ventricular and supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), bradycardia, electrocardiographic alterations (including second-degree heart block, QT/QTc interval prolongation, and ST segment depression), palpitations<span class="Bold">,</span> and syncope. Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT/QTc interval prolongation have been reported <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.2</a>)]</span>. </p>    <p> <span class="Underline">General:</span> Flushing. Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylactic reactions, angioedema, bronchospasm, cardiopulmonary arrest, hypotension, laryngeal edema, laryngospasm, shock, shortness of breath, stridor) have also been reported. A positive lymphocyte transformation test to ondansetron has been reported, which suggests immunologic sensitivity to ondansetron. </p>    <p> <span class="Underline">Hepatobiliary:</span> Liver enzyme abnormalities have been reported. Liver failure and death have been reported in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. </p>    <p> <span class="Underline">Local Reactions:</span> Pain, redness, and burning at site of injection. </p>    <p> <span class="Underline">Lower Respiratory:</span> Hiccups </p>    <p> <span class="Underline">Neurological:</span> Oculogyric crisis, appearing alone, as well as with other dystonic reactions. Transient dizziness during or shortly after intravenous infusion. </p>    <p> <span class="Underline">Skin:</span> Urticaria, Stevens-Johnson syndrome, and toxic epidermal necrolysis. </p>    <p> <span class="Underline">Eye Disorders:</span> Cases of transient blindness, predominantly during intravenous administration, have been reported. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. Transient blurred vision, in some cases associated with abnormalities of accommodation, have also been reported. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="s28"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s29"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Drugs Affecting Cytochrome P-450 Enzymes </h2>    <p class="First"> Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s30"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Apomorphine </h2>    <p class="First"> Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, concomitant use of apomorphine with ondansetron is contraindicated <span class="Italics">[see Contraindications (<a href="#s15">4</a>)].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s31"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Phenytoin, Carbamazepine, and Rifampin </h2>    <p class="First"> In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s32"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Tramadol </h2>    <p class="First"> Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small studies indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol. Patients on concomitant ondansetron self administered tramadol more frequently in these studies, leading to an increased cumulative dose in patient controlled administration (PCA) of tramadol. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s33"></a>   <a name="section-7.5"></a>    <p></p>    <h2>7.5 Serotonergic Drugs </h2>    <p class="First"> Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s34"></a>   <a name="section-7.6"></a>    <p></p>    <h2>7.6 Chemotherapy </h2>    <p class="First"> In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. </p>    <p> In a crossover study in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s35"></a>   <a name="section-7.7"></a>    <p></p>    <h2>7.7 Temazepam </h2>    <p class="First"> The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s36"></a>   <a name="section-7.8"></a>    <p></p>    <h2>7.8 Alfentanil and Atracurium </h2>    <p class="First"> Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="s37"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="s38"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy </h2>    <p class="First"> Pregnancy Category B. Reproduction studies have been performed in pregnant rats and rabbits at intravenous doses up to 4 mg/kg per day (approximately 1.4 and 2.9 times the recommended human intravenous dose of 0.15 mg/kg given three times a day, respectively, based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. </p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="s39"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers </h2>    <p class="First"> Ondansetron is excreted in the breast milk of rats. It is not known whether ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ondansetron is administered to a nursing woman. </p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="s40"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use </h2>    <p class="First"> Little information is available about the use of ondansetron in pediatric surgical patients younger than 1 month of age. <span class="Italics">[See Clinical Studies (<a href="#s68">14.2</a>)].</span> Little information is available about the use of ondansetron in pediatric cancer patients younger than 6 months of age. <span class="Italics">[See Clinical Studies (<a href="#s62">14.1</a>), Dosage and Administration (<a href="#s5">2</a>)].</span> </p>    <p> The clearance of ondansetron in pediatric patients 1 month to 4 months of age is slower and the half-life is ~2.5 fold longer than patients who are &gt; 4 to 24 months of age. As a precaution, it is recommended that patients less than 4 months of age receiving this drug be closely monitored. <span class="Italics">[See Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. </p>    <p> <span class="Bold">Ondansetron Prefilled Syringe: REQUIRES NO DILUTION FOR ADMINISTRATION FOR POSTOPERATIVE NAUSEA AND VOMITING. CAUTION: For pediatric patients less than 40 kg, a full 4 mg dose should NOT be given [see Dosage and Administration (<a href="#s9">2.2</a>)].</span> </p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="s41"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use </h2>    <p class="First"> Of the total number of subjects enrolled in cancer chemotherapy-induced and postoperative nausea and vomiting in US- and foreign-controlled clinical trials, 862 were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment is not needed in patients over the age of 65 <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s42"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Hepatic Impairment </h2>    <p class="First"> In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. In such patients, a total daily dose of 8 mg should not be exceeded <span class="Italics">[see Dosage and Administration (<a href="#s12">2.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s43"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.7 Renal Impairment </h2>    <p class="First"> Although plasma clearance is reduced in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min), no dosage adjustment is recommended <span class="Italics">[see Clinical Pharmacology (<a href="#s50">12.3</a>)]</span>. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a> <div class="Section toggle-content closed" data-sectioncode="42227-9">   <a name="s44"></a>  <a name="section-9"></a>   <p></p>    <p class="First"> Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="s45"></a>  <a name="section-10"></a>   <p></p>    <p class="First"> There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. Individual intravenous doses as large as 150 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events. These doses are more than 10 times the recommended daily dose. </p>   <p> In addition to the adverse reactions listed above, the following events have been described in the setting of ondansetron overdose: “Sudden blindness” (amaurosis) of 2 to 3 minutes' duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension (and faintness) occurred in another patient that took 48 mg of ondansetron hydrochloride tablets. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed. In all instances, the events resolved completely. </p>   <p> Pediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeding estimated ingestion of 5 mg/kg) in young children. Reported symptoms included somnolence, agitation, tachycardia, tachypnea, hypertension, flushing, mydriasis, diaphoresis, myoclonic movements, horizontal nystagmus, hyperreflexia, and seizure. Patients required supportive care, including intubation in some cases, with complete recovery without sequelae within 1 to 2 days. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="s46"></a>  <a name="section-11"></a>   <p></p>    <p class="First"> The active ingredient in Ondansetron Injection is ondansetron hydrochloride, a selective blocking agent of the serotonin 5-HT<span class="Sub">3</span> receptor type. Its chemical name is (&plusmn;) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, mono-hydrochloride, dihydrate. It has the following structural formula: </p>   <div class="Figure">    <a name="f01"></a>   <img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D01%2Ejpg" alt="Structural Formula" />  </div>   <p> The empirical formula is C<span class="Sub">18</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O•HCl•2H<span class="Sub">2</span>O, representing a molecular weight of 365.9. </p>   <p> Ondansetron HCl is a white to off-white powder that is soluble in water and normal saline. </p>   <p> Each 1 mL of aqueous solution contains 2 mg of ondansetron as the hydrochloride dihydrate; 9 mg of sodium chloride, USP; and 0.5 mg of citric acid monohydrate, USP and 0.25 mg of sodium citrate dihydrate, USP as buffers in Water for Injection, USP. </p>   <p> Ondansetron Injection, USP is a clear, colorless, nonpyrogenic, sterile solution for intravenous use. The pH of the injection solution is 3.3 to 4.0. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="s47"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="s48"></a>   <a name="section-12.1"></a>    <p></p>    <h2>12.1 Mechanism of Action </h2>    <p class="First"> Ondansetron is a selective 5-HT<span class="Sub">3</span> receptor antagonist. While ondansetron's mechanism of action has not been fully characterized, it is not a dopamine-receptor antagonist. </p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="s49"></a>   <a name="section-12.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics </h2>    <p class="First"> QTc interval prolongation was studied in a double blind, single intravenous dose, placebo- and positive-controlled, crossover study in 58 healthy subjects. The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline-correction was 19.5 (21.8) ms and 5.6 (7.4) ms after 15 minute intravenous infusions of 32 mg and 8 mg Ondansetron, respectively. A significant exposure-response relationship was identified between ondansetron concentration and ΔΔQTcF. Using the established exposure-response relationship, 24 mg infused intravenously over 15 min had a mean predicted (95% upper prediction interval) ΔΔQTcF of 14.0 (16.3) ms. In contrast, 16 mg infused intravenously over 15 min using the same model had a mean predicted (95% upper prediction interval) ΔΔQTcF of 9.1 (11.2) ms. </p>    <p> In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. In another study in six normal male volunteers, a 16-mg dose infused over 5 minutes showed no effect of the drug on cardiac output, heart rate, stroke volume, blood pressure, or electrocardiogram (ECG). Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations. In a gender-balanced pharmacodynamic study (n = 56), ondansetron 4 mg administered intravenously or intramuscularly was dynamically similar in the prevention of nausea and vomiting using the ipecacuanha model of emesis. </p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="s50"></a>   <a name="section-12.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics </h2>    <p class="First"> In normal adult volunteers, the following mean pharmacokinetic data have been determined following a single 0.15-mg/kg intravenous dose. </p>    <a name="t3"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 3. Pharmacokinetics in Normal Adult Volunteers </span>      </caption>      <colgroup>      <col align="left" width="20.000%" />       <col align="left" width="20.000%" />       <col align="left" width="20.000%" />       <col align="left" width="20.000%" />       <col align="left" width="20.000%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <br />Age-group<br />(years) </td>       <td class="Botrule Rrule Toprule" align="center" valign="top"> <br /> <br />n </td>       <td class="Botrule Rrule Toprule" align="center" valign="top">Peak Plasma Concentration (ng/mL) </td>       <td class="Botrule Rrule Toprule" align="center" valign="top">Mean Elimination<br />Half-life (h) </td>       <td class="Botrule Rrule Toprule" align="center" valign="top">Plasma Clearance<br />(L/h/kg) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">19-40 </td>       <td class="Botrule Rrule" align="center" valign="top">11 </td>       <td class="Botrule Rrule" align="center" valign="top">102 </td>       <td class="Botrule Rrule" align="center" valign="top">3.5 </td>       <td class="Botrule Rrule" align="center" valign="top">0.381 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">61-74 </td>       <td class="Botrule Rrule" align="center" valign="top">12 </td>       <td class="Botrule Rrule" align="center" valign="top">106 </td>       <td class="Botrule Rrule" align="center" valign="top">4.7 </td>       <td class="Botrule Rrule" align="center" valign="top">0.319 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">≥ 75 </td>       <td class="Botrule Rrule" align="center" valign="top">11 </td>       <td class="Botrule Rrule" align="center" valign="top">170 </td>       <td class="Botrule Rrule" align="center" valign="top">5.5 </td>       <td class="Botrule Rrule" align="center" valign="top">0.262 </td>       </tr>      </tbody>     </table>   </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s51"></a>    <a name="section-12.3.1"></a>     <p></p>     <p class="First"> <span class="Underline">Absorption</span>: A study was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared to a single intramuscular injection. Systemic exposure as measured by mean AUC were equivalent, with values of 156 [95% CI 136, 180] and 161 [95% CI 137, 190] ng•h/mL for intravenous and intramuscular groups, respectively. Mean peak plasma concentrations were 42.9 [95% CI 33.8, 54.4] ng/mL at 10 minutes after intravenous infusion and 31.9 [95% CI 26.3, 38.6] ng/mL at 41 minutes after intramuscular injection. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s52"></a>    <a name="section-12.3.2"></a>     <p></p>     <p class="First"> <span class="Underline">Distribution</span>: Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s53"></a>    <a name="section-12.3.3"></a>     <p></p>     <p class="First"> <span class="Underline">Metabolism:</span> Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. </p>     <p> Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron. The metabolites are observed in the urine. </p>     <p> In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2. The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor. </p>     <p> The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolisers of CYP2D6 and those who were extensive metabolisers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s54"></a>    <a name="section-12.3.4"></a>     <p></p>     <p class="First"> <span class="Underline">Elimination:</span> In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period. In a dose proportionality study, systemic exposure to 32 mg of ondansetron was not proportional to dose as measured by comparing dose-normalized AUC values to an 8-mg dose. This is consistent with a small decrease in systemic clearance with increasing plasma concentrations. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s55"></a>    <a name="section-12.3.5"></a>     <p></p>     <p class="First"> <span class="Underline">Geriatrics:</span> A reduction in clearance and increase in elimination half-life are seen in patients over 75 years of age. In clinical trials with cancer patients, safety and efficacy were similar in patients over 65 years of age and those under 65 years of age; there was an insufficient number of patients over 75 years of age to permit conclusions in that age-group. No dosage adjustment is recommended in the elderly. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s56"></a>    <a name="section-12.3.6"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics:</span> Pharmacokinetic samples were collected from 74 cancer patients 6 to 48 months of age, who received a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses during a safety and efficacy trial. These data were combined with sequential pharmacokinetics data from 41 surgery patients 1 month to 24 months of age, who received a single dose of 0.1 mg/kg of intravenous ondansetron prior to surgery with general anesthesia, and a population pharmacokinetic analysis was performed on the combined data set. The results of this analysis are included in <a href="#t4">Table 4</a> and are compared to the pharmacokinetic results in cancer patients 4 to 18 years of age. </p>     <a name="t4"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 4. Pharmacokinetics in Pediatric Cancer Patients 1 Month to 18 Years of Age </span>       </caption>       <colgroup>       <col align="left" width="25.025%" />        <col align="left" width="14.723%" />        <col align="left" width="20.084%" />        <col align="left" width="20.084%" />        <col align="left" width="20.084%" />       </colgroup>      <tfoot>        <tr class="First Last">         <td align="left" colspan="5" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Population PK (Pharmacokinetic) Patients: 64% cancer patients and 36% surgery patients. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"> <br />Subjects and Age Group </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br />N </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">CL<br />(L/h/kg) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Vd<span class="Sub">ss</span> <br />(L/kg) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">T<span class="Sub">&frac12;</span> <br />(h) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" colspan="2" valign="top">Geometric Mean </td>        <td class="Botrule Rrule" align="center" valign="top">Mean </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Pediatric Cancer Patients<br />4 to 18 years of age </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />N = 21 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.599 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />1.9 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />2.8 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Population PK Patients<span class="Sup">a</span> <br />1 month to 48 months of age </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />N = 115 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.582 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />3.65 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />4.9 </td>        </tr>       </tbody>      </table>    </div>     <p> Based on the population pharmacokinetic analysis, cancer patients 6 to 48 months of age who receive a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses would be expected to achieve a systemic exposure (AUC) consistent with the exposure achieved in previous pediatric studies in cancer patients (4 to 18 years of age) at similar doses. </p>     <p> In a study of 21 pediatric patients (3 to 12 years of age) who were undergoing surgery requiring anesthesia for a duration of 45 minutes to 2 hours, a single intravenous dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8 to 12 years), was administered immediately prior to anesthesia induction. Mean weight-normalized clearance and volume of distribution values in these pediatric surgical patients were similar to those previously reported for young adults. Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours). </p>     <p> In a study of 51 pediatric patients (1 month to 24 months of age) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery. As shown in <a href="#t5">Table 5</a>, the 41 patients with pharmacokinetic data were divided into 2 groups, patients 1 month to 4 months of age and patients 5 to 24 months of age, and are compared to pediatric patients 3 to 12 years of age. </p>     <a name="t5"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 5. Pharmacokinetics in Pediatric Surgery Patients 1 Month to 12 Years of Age </span>       </caption>       <colgroup>       <col align="left" width="25.025%" />        <col align="left" width="14.723%" />        <col align="left" width="20.084%" />        <col align="left" width="20.084%" />        <col align="left" width="20.084%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"> <br />Subjects and Age Group </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br />N </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">CL<br />(L/h/kg) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Vd<span class="Sub">ss</span> <br />(L/kg) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">T<span class="Sub">&frac12;</span> <br />(h) </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" colspan="2" valign="top">Geometric Mean </td>        <td class="Botrule Rrule" align="center" valign="top">Mean </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Pediatric Surgery Patients<br />3 to 12 years of age </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />N = 21 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.439 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />1.65 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />2.9 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Pediatric Surgery Patients<br />5 to 24 months of age </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />N = 22 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.581 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />2.3 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />2.9 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Pediatric Surgery Patients<br />1 month to 4 months of age </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />N = 19 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.401 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />3.5 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />6.7 </td>        </tr>       </tbody>      </table>    </div>     <p> In general, surgical and cancer pediatric patients younger than 18 years tend to have a higher ondansetron clearance compared to adults leading to a shorter half-life in most pediatric patients. In patients 1 month to 4 months of age, a longer half-life was observed due to the higher volume of distribution in this age group. </p>     <p> In a study of 21 pediatric cancer patients (4 to 18 years of age) who received three intravenous doses of 0.15 mg/kg of ondansetron at 4-hour intervals, patients older than 15 years of age exhibited ondansetron pharmacokinetic parameters similar to those of adults. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s57"></a>    <a name="section-12.3.7"></a>     <p></p>     <p class="First"> <span class="Underline">Renal Impairment</span>: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). This reduction in clearance is variable and was not consistent with an increase in half-life. No reduction in dose or dosing frequency in these patients is warranted. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s58"></a>    <a name="section-12.3.8"></a>     <p></p>     <p class="First"> <span class="Underline">Hepatic Impairment</span>: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in those without hepatic impairment. In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours. In patients with severe hepatic impairment, a total daily dose of 8 mg should not be exceeded. </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="s59"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="s60"></a>   <a name="section-13.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>    <p class="First"> Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg per day, respectively (approximately 3.6 and 5.4 times the recommended human intravenous dose of 0.15 mg/kg given three times a day, based on body surface area). Ondansetron was not mutagenic in standard tests for mutagenicity. </p>    <p> Oral administration of ondansetron up to 15 mg/kg per day (approximately 3.8 times the recommended human intravenous dose, based on body surface area) did not affect fertility or general reproductive performance of male and female rats. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="s61"></a>  <a name="section-14"></a>   <p></p>    <p class="First"> The clinical efficacy of ondansetron hydrochloride, the active ingredient of Ondansetron Injection, was assessed in clinical trials as described below. </p>   <div class="Section" data-sectioncode="42229-5">    <a name="s62"></a>   <a name="section-14.1"></a>    <p></p>    <h2>14.1 Chemotherapy-Induced Nausea and Vomiting </h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s63"></a>    <a name="section-14.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Adults</span>: In a double-blind study of three different dosing regimens of Ondansetron Injection, 0.015 mg/kg, 0.15 mg/kg, and 0.30 mg/kg, each given three times during the course of cancer chemotherapy, the 0.15-mg/kg dosing regimen was more effective than the 0.015-mg/kg dosing regimen. The 0.30-mg/kg dosing regimen was not shown to be more effective than the 0.15-mg/kg dosing regimen. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s64"></a>    <a name="section-14.1.2"></a>     <p></p>     <p class="First"> <span class="Italics">Cisplatin-Based Chemotherapy:</span> In a double-blind study in 28 patients, Ondansetron Injection (three 0.15-mg/kg doses) was significantly more effective than placebo in preventing nausea and vomiting induced by cisplatin-based chemotherapy. Therapeutic response was as shown in <a href="#t6">Table 6</a>. </p>     <a name="t6"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 6. Therapeutic Response in Prevention of Chemotherapy-Induced Nausea and Vomiting in Single-Day Cisplatin Therapy<span class="Sup">a</span> in Adults </span>       </caption>       <colgroup>       <col align="left" width="26.557%" />        <col align="left" width="24.481%" />        <col align="left" width="24.481%" />        <col align="left" width="24.481%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Chemotherapy was high dose (100 and 120 mg/m<span class="Sup">2</span>; Ondansetron Injection n = 6, placebo n = 5) or moderate dose (50 and 80 mg/m<span class="Sup">2</span>; Ondansetron Injection n = 8, placebo n = 9). Other </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">chemotherapeutic agents included fluorouracil, doxorubicin, and cyclophosphamide. There was no </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">difference between treatments in the types of chemotherapy that would account for differences in </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">response. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Efficacy based on &quot;all patients treated&quot; analysis. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">c</span> Median undefined since at least 50% of the patients were rescued or had more than five emetic </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">episodes. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">d</span> Visual analog scale assessment of nausea: 0 = no nausea, 100 = nausea as bad as it can be. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">e</span> Visual analog scale assessment of satisfaction: 0 = not at all satisfied, 100 = totally satisfied. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron Injection<br />(0.15 mg/kg x 3) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br />Placebo </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br /> <span class="Italics">P</span> Value<span class="Sup">b</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Number of patients </td>        <td class="Botrule Rrule" align="center" valign="top">14 </td>        <td class="Botrule Rrule" align="center" valign="top">14 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Treatment response<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1-2 Emetic episodes<br />&nbsp; &nbsp;3-5 Emetic episodes<br />&nbsp; &nbsp;More than 5 emetic<br />&nbsp; &nbsp;episodes/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />2 (14%)<br />8 (57%)<br />2 (14%)<br />2 (14%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0 (0%)<br />0 (0%)<br />1 (7%)<br />13 (93%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br /> <br /> <br />0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median number of emetic episodes </td>        <td class="Botrule Rrule" align="center" valign="top">1.5 </td>        <td class="Botrule Rrule" align="center" valign="top">Undefined<span class="Sup">c</span></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median time to first emetic episode (h) </td>        <td class="Botrule Rrule" align="center" valign="top">11.6 </td>        <td class="Botrule Rrule" align="center" valign="top">2.8 </td>        <td class="Botrule Rrule" align="center" valign="top">0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median nausea scores (0-100)<span class="Sup">d</span></td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        <td class="Botrule Rrule" align="center" valign="top">59 </td>        <td class="Botrule Rrule" align="center" valign="top">0.034 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Global satisfaction with control of nausea and vomiting (0-100)<span class="Sup">e</span></td>        <td class="Botrule Rrule" align="center" valign="top">96 </td>        <td class="Botrule Rrule" align="center" valign="top">10.5 </td>        <td class="Botrule Rrule" align="center" valign="top">0.009 </td>        </tr>       </tbody>      </table>    </div>     <p> Ondansetron injection (0.15-mg/kg x 3 doses) was compared with metoclopramide (2 mg/kg x 6 doses) in a single-blind trial in 307 patients receiving cisplatin ≥ 100 mg/m<span class="Sup">2</span> with or without other chemotherapeutic agents. Patients received the first dose of ondansetron or metoclopramide 30 minutes before cisplatin. Two additional ondansetron doses were administered 4 and 8 hours later, or five additional metoclopramide doses were administered 2, 4, 7, 10, and 13 hours later. Cisplatin was administered over a period of 3 hours or less. Episodes of vomiting and retching were tabulated over the period of 24 hours after cisplatin. The results of this study are summarized in <a href="#t7">Table 7</a>. </p>     <a name="t7"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 7. Therapeutic Response in Prevention of Vomiting Induced by Cisplatin (≥ 100 mg/m<span class="Sup">2</span>) Single-Day Therapy<span class="Sup">a</span> in Adults </span>       </caption>       <colgroup>       <col align="left" width="44.125%" />        <col align="left" width="22.050%" />        <col align="left" width="19.125%" />        <col align="left" width="14.700%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> In addition to cisplatin, 68% of patients received other chemotherapeutic agents, including cyclophosphamide, etoposide, and fluorouracil. There was no difference between treatments in the types of chemotherapy that would account for differences in response. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Visual analog scale assessment: 0 = not at all satisfied, 100 = totally satisfied. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron Injection </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Metoclopramide </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Italics">P</span> Value </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Dose </td>        <td class="Botrule Rrule" align="center" valign="top">0.15 mg/kg x 3 </td>        <td class="Botrule Rrule" align="center" valign="top">2 mg/kg x 6 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Number of patients in efficacy population </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />136 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />138 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Treatment response<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1-2 Emetic episodes<br />&nbsp; &nbsp;3-5 Emetic episodes<br />&nbsp; &nbsp;More than 5 emetic episodes/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />54 (40%)<br />34 (25%)<br />19 (14%)<br />29 (21%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />41 (30%)<br />30 (22%)<br />18 (13%)<br />49 (36%) </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Comparison of treatments with respect to<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;More than 5 emetic episodes/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />54/136<br />29/136 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />41/138<br />49/138 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.083<br />0.009 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median number of emetic episodes </td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">2 </td>        <td class="Botrule Rrule" align="center" valign="top">0.005 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median time to first emetic episode (h) </td>        <td class="Botrule Rrule" align="center" valign="top">20.5 </td>        <td class="Botrule Rrule" align="center" valign="top">4.3 </td>        <td class="Botrule Rrule" align="center" valign="top">&lt; 0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Global satisfaction with control of nausea and vomiting (0-100)<span class="Sup">b</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />85 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />63 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Acute dystonic reactions </td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">8 </td>        <td class="Botrule Rrule" align="center" valign="top">0.005 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Akathisia </td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">10 </td>        <td class="Botrule Rrule" align="center" valign="top">0.002 </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s65"></a>    <a name="section-14.1.3"></a>     <p></p>     <p class="First"> <span class="Italics">Cyclophosphamide-Based Chemotherapy:</span> In a double-blind, placebo-controlled study of Ondansetron Injection (three 0.15-mg/kg doses) in 20 patients receiving cyclophosphamide (500 to 600 mg/m<span class="Sup">2</span>) chemotherapy, Ondansetron Injection was significantly more effective than placebo in preventing nausea and vomiting. The results are summarized in <a href="#t8">Table 8</a>. </p>     <a name="t8"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 8. Therapeutic Response in Prevention of Chemotherapy-Induced Nausea and Vomiting in Single-Day Cyclophosphamide Therapy<span class="Sup">a</span> in Adults </span>       </caption>       <colgroup>       <col align="left" width="43.089%" />        <col align="left" width="19.595%" />        <col align="left" width="22.394%" />        <col align="left" width="14.921%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Chemotherapy consisted of cyclophosphamide in all patients, plus other agents, including </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">fluorouracil, doxorubicin, methotrexate, and vincristine. There was no difference between </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote">treatments in the type of chemotherapy that would account for differences in response. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Efficacy based on &quot;all patients treated&quot; analysis. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">c</span> Median undefined since at least 50% of patients did not have any emetic episodes. </p> </td>        </tr>        <tr>         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">d</span> Visual analog scale assessment of nausea: 0 = no nausea, 100 = nausea as bad as it can be. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">e</span> Visual analog scale assessment of satisfaction: 0 = not at all satisfied, 100 = totally satisfied. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron Injection<br />(0.15 mg/kg x 3) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br /> <br />Placebo </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br /> <br /> <span class="Italics">P</span> Value<span class="Sup">b</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Number of patients </td>        <td class="Botrule Rrule" align="center" valign="top">10 </td>        <td class="Botrule Rrule" align="center" valign="top">10 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Treatment response<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1-2 Emetic episodes<br />&nbsp; &nbsp;3-5 Emetic episodes<br />&nbsp; &nbsp;More than 5 emetic episodes/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />7 (70%)<br />0 (0%)<br />2 (20%)<br />1 (10%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0 (0%)<br />2 (20%)<br />4 (40%)<br />4 (40%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.001<br /> <br /> <br />0.131 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median number of emetic episodes </td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">4 </td>        <td class="Botrule Rrule" align="center" valign="top">0.008 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median time to first emetic episode (h) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />Undefined<span class="Sup">c</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />8.79 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Median nausea scores (0-100)<span class="Sup">d</span></td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">60 </td>        <td class="Botrule Rrule" align="center" valign="top">0.001 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Global satisfaction with control of nausea and vomiting (0-100)<span class="Sup">e</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />100 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />52 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />0.008 </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s66"></a>    <a name="section-14.1.4"></a>     <p></p>     <p class="First"> <span class="Italics">Re-treatment:</span> In uncontrolled trials, 127 patients receiving cisplatin (median dose, 100 mg/m<span class="Sup">2</span>) and ondansetron who had two or fewer emetic episodes were re-treated with ondansetron and chemotherapy, mainly cisplatin, for a total of 269 re-treatment courses (median, 2; range, 1 to 10). No emetic episodes occurred in 160 (59%), and two or fewer emetic episodes occurred in 217 (81%) re-treatment courses. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s67"></a>    <a name="section-14.1.5"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics</span>: Four open-label, noncomparative (one US, three foreign) trials have been performed with 209 pediatric cancer patients 4 to 18 years of age given a variety of cisplatin or noncisplatin regimens. In the three foreign trials, the initial Ondansetron injection ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg. This was followed by the oral administration of ondansetron ranging from 4 to 24 mg daily for 3 days. In the US trial, Ondansetron injection was administered intravenously (only) in three doses of 0.15 mg/kg each for a total daily dose of 7.2 to 39 mg. In these studies, 58% of the 196 evaluable patients had a complete response (no emetic episodes) on day 1. Thus, prevention of vomiting in these pediatric patients was essentially the same as for patients older than 18 years of age. </p>     <p> An open-label, multicenter, noncomparative trial has been performed in 75 pediatric cancer patients 6 to 48 months of age receiving at least one moderately or highly emetogenic chemotherapeutic agent. Fifty-seven percent (57%) were females; 67% were white, 18% were American Hispanic, and 15% were black patients. Ondansetron Injection was administered intravenously over 15 minutes in three doses of 0.15 mg/kg. The first dose was administered 30 minutes before the start of chemotherapy, the second and third doses were administered 4 and 8 hours after the first dose, respectively. Eighteen patients (25%) received routine prophylactic dexamethasone (i.e., not given as rescue). Of the 75 evaluable patients, 56% had a complete response (no emetic episodes) on day 1. Thus, prevention of vomiting in these pediatric patients was comparable to the prevention of vomiting in patients 4 years of age and older. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s68"></a>   <a name="section-14.2"></a>    <p></p>    <h2>14.2 Prevention of Postoperative Nausea and/or Vomiting </h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s69"></a>    <a name="section-14.2.1"></a>     <p></p>     <p class="First"> <span class="Underline">Adults:</span> Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients. Ondansetron Injection (4 mg) intravenous given over 2 to 5 minutes was significantly more effective than placebo. The results of these studies are summarized in <a href="#t9">Table 9</a>. </p>     <a name="t9"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 9. Therapeutic Response in Prevention of Postoperative Nausea and Vomiting in Adult Patients </span>       </caption>       <colgroup>       <col align="left" width="43.464%" />        <col align="left" width="21.745%" />        <col align="left" width="20.295%" />        <col align="left" width="14.496%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron 4 mg Intravenous </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Placebo </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Italics">P</span> Value </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 1 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Emetic episodes:<br />Number of patients<br />Treatment response over 24-h<br />postoperative period<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1 Emetic episode<br />&nbsp; &nbsp;More than 1 emetic episode/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />136<br /> <br /> <br />103 (76%)<br />13 (10%)<br />20 (15%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />139<br /> <br /> <br />64 (46%)<br />17 (12%)<br />58 (42%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br /> <br /> <br />&lt; 0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Nausea assessments:<br />Number of patients<br />No nausea over 24-h postoperative<br />period </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />134<br />56 (42%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />136<br />39 (29%) </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 2 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Emetic episodes:<br />Number of patients<br />Treatment response over 24-h<br />postoperative period<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1 Emetic episode<br />&nbsp; &nbsp;More than 1 emetic episode/rescued </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />136<br /> <br /> <br />85 (63%)<br />16 (12%)<br />35 (26%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />143<br /> <br /> <br />63 (44%)<br />29 (20%)<br />51 (36%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br /> <br /> <br />0.002 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Nausea assessments:<br />Number of patients<br />No nausea over 24-h postoperative<br />period </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />125<br />48 (38%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />133<br />42 (32%) </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>       </tbody>      </table>    </div>     <p> The study populations in <a href="#t9">Table 9</a> consisted mainly of females undergoing laparoscopic procedures. </p>     <p> In a placebo-controlled study conducted in 468 males undergoing outpatient procedures, a single 4-mg intravenous ondansetron dose prevented postoperative vomiting over a 24-hour study period in 79% of males receiving drug compared to 63% of males receiving placebo (<span class="Italics">P</span> &lt; 0.001<span class="Italics">).</span> </p>     <p> Two other placebo-controlled studies were conducted in 2,792 patients undergoing major abdominal or gynecological surgeries to evaluate a single 4-mg or 8-mg intravenous ondansetron dose for prevention of postoperative nausea and vomiting over a 24-hour study period. At the 4-mg dosage, 59% of patients receiving ondansetron versus 45% receiving placebo in the first study (<span class="Italics">P</span> &lt; 0.001) and 41% of patients receiving ondansetron versus 30% receiving placebo in the second study (<span class="Italics">P</span> = 0.001) experienced no emetic episodes. No additional benefit was observed in patients who received intravenous ondansetron 8 mg compared to patients who received intravenous ondansetron 4 mg. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s70"></a>    <a name="section-14.2.2"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics:</span> Three double-blind, placebo-controlled studies have been performed (one US, two foreign) in 1,049 male and female patients (2 to 12 years of age) undergoing general anesthesia with nitrous oxide. The surgical procedures included tonsillectomy with or without adenoidectomy, strabismus surgery, herniorrhaphy, and orchidopexy. Patients were randomized to either single intravenous doses of ondansetron (0.1 mg/kg for pediatric patients weighing 40 kg or less, 4 mg for pediatric patients weighing more than 40 kg) or placebo. Study drug was administered over at least 30 seconds, immediately prior to or following anesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarized in <a href="#t10">Table 10</a>. </p>     <a name="t10"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 10. Therapeutic Response in Prevention of Postoperative Nausea and Vomiting in Pediatric Patients 2 to 12 Years of Age </span>       </caption>       <colgroup>       <col align="left" width="43.464%" />        <col align="left" width="21.745%" />        <col align="left" width="20.295%" />        <col align="left" width="14.496%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Failure was one or more emetic episodes, rescued, or withdrawn. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Nausea measured as none, mild, or severe. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Treatment Response Over 24 Hours </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron<br />n (%) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Placebo<br />n (%) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"> <br /> <span class="Italics">P</span> Value </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 1<br />Number of patients<br />0 Emetic episodes<br />Failure<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />205<br />140 (68%)<br />65 (32%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />210<br />82 (39%)<br />128 (61%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br />≤ 0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 2<br />Number of patients<br />0 Emetic episodes<br />Failure<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />112<br />68 (61%)<br />44 (39%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />110<br />38 (35%)<br />72 (65%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br />≤ 0.001 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 3<br />Number of patients<br />0 Emetic episodes<br />Failure<span class="Sup">a</span> <br /> <br />Nausea assessments<span class="Sup">b</span>:<br />Number of patients<br />None </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />206<br />123 (60%)<br />83 (40%)<br /> <br /> <br />185<br />119 (64%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />206<br />96 (47%)<br />110 (53%)<br /> <br /> <br />191<br />99 (52%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br />≤ 0.01<br /> <br /> <br /> <br />≤ 0.01 </td>        </tr>       </tbody>      </table>    </div>     <p> A double-blind, multicenter, placebo-controlled study was conducted in 670 pediatric patients 1 month to 24 months of age who were undergoing routine surgery under general anesthesia. Seventy-five percent (75%) were males; 64% were white, 15% were black, 13% were American Hispanic, 2% were Asian, and 6% were “other race” patients. A single 0.1-mg/kg intravenous dose of ondansetron administered within 5 minutes following induction of anesthesia was statistically significantly more effective than placebo in preventing vomiting. In the placebo group, 28% of patients experienced vomiting compared to 11% of subjects who received ondansetron (<span class="Italics">P</span> ≤ 0.01). Overall, 32 (10%) of placebo patients and 18 (5%) of patients who received ondansetron received antiemetic rescue medication(s) or prematurely withdrew from the study. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s71"></a>   <a name="section-14.3"></a>    <p></p>    <h2>14.3 Prevention of Further Postoperative Nausea and Vomiting </h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s72"></a>    <a name="section-14.3.1"></a>     <p></p>     <p class="First"> <span class="Underline">Adults:</span> Adult surgical patients receiving general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) who received no prophylactic antiemetics and who experienced nausea and/or vomiting within 2 hours postoperatively were evaluated in two double-blind US studies involving 441 patients. Patients who experienced an episode of postoperative nausea and/or vomiting were given Ondansetron Injection (4 mg) intravenous over 2 to 5 minutes, and this was significantly more effective than placebo. The results of these studies are summarized in <a href="#t11">Table 11</a>. </p>     <a name="t11"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 11. Therapeutic Response in Prevention of Further Postoperative Nausea and Vomiting in Adult Patients </span>       </caption>       <colgroup>       <col align="left" width="43.650%" />        <col align="left" width="21.550%" />        <col align="left" width="20.300%" />        <col align="left" width="14.500%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> After administration of study drug. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Nausea measured on a scale of 0-10 with 0 = no nausea, 10 = nausea as bad as it can be. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron 4 mg Intravenous </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Placebo </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Italics">P</span> Value </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 1 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Emetic episodes:<br />Number of patients<br />Treatment response 24 h after study drug<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1 Emetic episode<br />&nbsp; &nbsp;More than 1 emetic episode/rescued<br />Median time to first emetic episode (min)<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />104<br /> <br />49 (47%)<br />12 (12%)<br />43 (41%)<br />55.0 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />117<br /> <br />19 (16%)<br />9 (8%)<br />89 (76%)<br />43.0 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br /> <br />&lt; 0.001 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Nausea assessments:<br />Number of patients<br />Mean nausea score over 24-h postoperative<br />period<span class="Sup">b</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />98<br />1.7 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />102<br />3.1 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Study 2 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Emetic episodes:<br />Number of patients<br />Treatment response 24 h after study drug<br />&nbsp; &nbsp;0 Emetic episodes<br />&nbsp; &nbsp;1 Emetic episode<br />&nbsp; &nbsp;More than 1 emetic episode/rescued<br />Median time to first emetic episode (min)<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />112<br /> <br />49 (44%)<br />14 (13%)<br />49 (44%)<br />60.5 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />108<br /> <br />28 (26%)<br />3 (3%)<br />77 (71%)<br />34.0 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br /> <br /> <br />0.006 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Nausea assessments:<br />Number of patients<br />Mean nausea score over 24-h postoperative<br />period<span class="Sup">b</span></td>        <td class="Botrule Rrule" align="center" valign="top"> <br />105<br />1.9 </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />85<br />2.9 </td>        <td class="Botrule Rrule" align="center" valign="top"></td>        </tr>       </tbody>      </table>    </div>     <p>The study populations in <a href="#t11">Table 11</a> consisted mainly of women undergoing laparoscopic procedures. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s73"></a>    <a name="section-14.3.2"></a>     <p></p>     <p class="First"> <span class="Italics">Repeat Dosing in Adults:</span> In patients who do not achieve adequate control of postoperative nausea and vomiting following a single, prophylactic, preinduction, intravenous dose of ondansetron 4 mg, administration of a second intravenous dose of ondansetron 4 mg postoperatively does not provide additional control of nausea and vomiting. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s74"></a>    <a name="section-14.3.3"></a>     <p></p>     <p class="First"> <span class="Underline">Pediatrics:</span> One double-blind, placebo-controlled, US study was performed in 351 male and female outpatients (2 to 12 years of age) who received general anesthesia with nitrous oxide and no prophylactic antiemetics. Surgical procedures were unrestricted. Patients who experienced two or more emetic episodes within 2 hours following discontinuation of nitrous oxide were randomized to either single intravenous doses of ondansetron (0.1 mg/kg for pediatric patients weighing 40 kg or less, 4 mg for pediatric patients weighing more than 40 kg) or placebo administered over at least 30 seconds. Ondansetron was significantly more effective than placebo in preventing further episodes of nausea and vomiting. The results of the study are summarized in <a href="#t12">Table 12</a>. </p>     <a name="t12"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 12. Therapeutic Response in Prevention of Further Postoperative Nausea and Vomiting in Pediatric Patients 2 to 12 Years of Age </span>       </caption>       <colgroup>       <col align="left" width="25.000%" />        <col align="left" width="25.000%" />        <col align="left" width="25.000%" />        <col align="left" width="25.000%" />       </colgroup>      <tfoot>        <tr class="First Last">         <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Failure was one or more emetic episodes, rescued, or withdrawn. </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Treatment Response Over 24 Hours </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Ondansetron<br />n (%) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top">Placebo<br />n (%) </td>        <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Italics">P</span> Value </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Number of patients<br />0 Emetic episodes<br />Failure<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top">180<br />96 (53%)<br />84 (47%) </td>        <td class="Botrule Rrule" align="center" valign="top">171<br />29 (17%)<br />142 (83%) </td>        <td class="Botrule Rrule" align="center" valign="top"> <br />≤ 0.001 </td>        </tr>       </tbody>      </table>    </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="s75"></a>  <a name="section-15"></a>   <p></p>    <p class="First">Ondansetron Injection, 2 mg/mL, is supplied as follows: </p>   <p>4 mg/2 mL in a 2 mL pre-filled disposable single-use syringe, NDC 76045-103-20 </p>   <p>Available in a carton of twenty-four (24) syringes. </p>   <div class="Section" data-sectioncode="44425-7">    <a name="s76"></a>   <a name="section-15.1"></a>    <p></p>    <p class="First"> <span class="Bold">Storage:</span> Store at 20&deg; to 25&deg;C (68&deg; to 77&deg;F) [See USP Controlled Room Temperature.] </p>    <p>Product may also be stored in a refrigerator 2&deg; to 8&deg;C (36&deg; to 46&deg;F). </p>    <p>Protect from light. Retain in carton until time of use. </p>    <p> <span class="Bold">Do not place syringe on a sterile field</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INSTRUCTIONS FOR USE</a> <div class="Section toggle-content closed" data-sectioncode="59845-8">   <a name="s77"></a>  <a name="section-16"></a>   <p></p>   <p class="First"> <span class="Bold Underline">Instructions For Use:</span> </p>   <p>CAUTION: Certain glass syringes may malfunction, break or clog when connected to some Needleless Luer Access Devices (NLADs) and needles. This syringe has a larger internal syringe tip and an external collar (luer collar). The external collar must remain attached to the syringe. Data show that the syringe achieves acceptable connections with the BD Eclipse™ Needle and the Terumo SurGuard2™ Safety Needle and with the following non-center post NLADs: Alaris SMARTSITE™, B-Braun ULTRASITE™, BD-Q SYTE™, Maximum MAX PLUS™, and B-Braun SAFSITE™. The data also show acceptable connections are achieved to the center post ICU Medical CLAVE™. However, spontaneous disconnection of this glass syringe from needles and NLADs with leakage of drug product may occur. Assure that the needle or NLAD is securely attached before beginning the injection. Visually inspect the glass syringe-needle or glass syringe –NLAD connection before and during drug administration. Do not remove the clear plastic wrap around the external collar. </p>   <div class="Figure">    <a name="f02"></a>   <img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D02%2Ejpg" alt="Figure" />  </div>   <ol class="Arabic">    <li>Inspect the outer packaging (blister pack):<br />Verify:    <dl class="Disc">      <dt>      -      </dt>      <dd>      blister integrity      </dd>      <dt>      -      </dt>      <dd>      expiration date      </dd>      <dt>      -      </dt>      <dd>      drug name      </dd>      <dt>      -      </dt>      <dd>      drug strength      </dd>      <dt>      -      </dt>      <dd>      dose volume      </dd>      <dt>      -      </dt>      <dd>      route of administration      </dd>      <dt>      -      </dt>      <dd>      sterile field applicability      </dd>     </dl>Do not use if package has been damaged. </li>    <li>Peel open the paper (top web) of the outer packaging that displays the product information to access the syringe. Do not pop syringe through. </li>    <li>Bend the plastic part of the outer packaging (thermoform) so as to present the plunger rod for syringe removal.    <div class="Figure">      <a name="f03"></a>     <img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D03%2Ejpg" alt="Figure" />    </div> </li>    <li>Perform visual inspection on the syringe<br />Verify:    <dl class="Disc">      <dt>      -      </dt>      <dd>      absence of syringe damage      </dd>      <dt>      -      </dt>      <dd>      absence of external particles      </dd>      <dt>      -      </dt>      <dd>      absence of internal particles      </dd>      <dt>      -      </dt>      <dd>      proper drug color      </dd>      <dt>      -      </dt>      <dd>      expiration date      </dd>      <dt>      -      </dt>      <dd>      drug name      </dd>      <dt>      -      </dt>      <dd>      drug strength      </dd>      <dt>      -      </dt>      <dd>      dose volume      </dd>      <dt>      -      </dt>      <dd>      route of administration      </dd>      <dt>      -      </dt>      <dd>      sterile field applicability      </dd>      <dt>      -      </dt>      <dd>      integrity of the plastic wrap around the external collar      </dd>     </dl> </li>    <li>Do not remove plastic wrap around the external collar. Without removing the tip cap, push plunger rod slightly to break the stopper loose. </li>    <li>Do not remove plastic wrap around the external collar. Remove tip cap by twisting it off.    <div class="Figure">      <a name="f04"></a>     <img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D04%2Ejpg" alt="Figure" />    </div> </li>    <li>Discard the tip cap. </li>    <li>Expel air bubble. </li>    <li>Adjust dose by expelling extra volume (where applicable) from the syringe into sterile material prior to administration. </li>    <li>Connect the syringe to appropriate injection connection depending on route of administration. Before injection, ensure that the syringe is securely attached to the needle or needleless luer access device. </li>    <li>Depress plunger rod to deliver medication. </li>    <li>Remove syringe from needleless luer access device (if applicable) and discard into appropriate receptacle. If delivering medication via intramuscular route, do not recap needle. </li>   </ol>   <p> <span class="Bold">NOTES:</span> </p>   <dl class="Disc">    <dt>    -    </dt>    <dd>    All steps must be done sequentially.    </dd>    <dt>    -    </dt>    <dd>     <span class="Bold">Do not autoclave syringe.</span>    </dd>    <dt>    -    </dt>    <dd>     <span class="Bold">Do not use this product on a sterile field.</span>    </dd>    <dt>    -    </dt>    <dd>    Do not introduce any other fluid into the syringe at any time.    </dd>    <dt>    -    </dt>    <dd>    This product is for single dose only.    </dd>   </dl>   <p>For more information concerning this drug or to report an adverse event please call BD Rx Inc., at 1-866-943-8534. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="s78"></a>  <a name="section-17"></a>   <p></p>    <ul class="Disc">    <li>Patients should be informed that Ondansetron Injection may cause serious cardiac arrhythmias such as QT prolongation. Patients should be instructed to tell their healthcare provider right away if they perceive a change in their heart rate, if they feel lightheaded, or if they have a syncopal episode. </li>    <li>Patients should be informed that the chances of developing severe cardiac arrhythmias such as QT prolongation and Torsade de Pointes are higher in the following people:    <ul class="Circle">      <li>Patients with a personal or family history of abnormal heart rhythms, such as congenital long QT syndrome; </li>      <li>Patients who take medications, such as diuretics, which may cause electrolyte abnormalities </li>      <li>Patients with hypokalemia or hypomagnesemia </li>     </ul> <p class="First">Ondansetron Injection should be avoided in these patients, since they may be more at risk for cardiac arrhythmias such as QT prolongation and Torsade de Pointes. </p> </li>    <li>Advise patients of the possibility of serotonin syndrome with concomitant use of <br />Ondansetron and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms with or without gastrointestinal symptoms. </li>    <li>Inform patients that Ondansetron Injection may cause hypersensitivity reactions, some as severe as anaphylaxis and bronchospasm. The patient should report any signs and symptoms of hypersensitivity reactions, including fever, chills, rash, or breathing problems. </li>    <li>The patient should report the use of all medications, especially apomorphine, to their healthcare provider. Concomitant use of apomorphine and Ondansetron Injection may cause a significant drop in blood pressure and loss of consciousness. </li>    <li>Inform patients that Ondansetron may cause headache, drowsiness/sedation, constipation, fever and diarrhea. </li>   </ul>   <p class="First">Rev 10/14<br />P0106 </p>   <p> <a name="f05"></a><img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D05%2Ejpg" alt="Logo" /></p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s79"></a>  <a name="section-18"></a>   <p></p>   <p class="First">Principal Display Panel – Carton Label </p>   <p>Rx Only </p>   <p>NDC 76045-103-20 </p>   <p> <span class="Bold">BD Simplist </span>™ </p>   <p> <span class="Bold">Ondansetron<br />Injection, USP </span> </p>   <p> <span class="Bold">4 </span> mg/<span class="Bold">2 </span> mL (<span class="Bold">2 </span> mg/mL) </p>   <p> <span class="Bold">For Intravenous or Intramuscular use. </span> </p>   <p> <span class="Bold">Do NOT place syringe on a Sterile Field </span> </p>   <p>24 x 2 mL Prefilled single-use syringes </p>   <p> <span class="Bold">Discard unused portion. </span> </p>   <p>BD Rx Inc., Franklin Lakes, NJ 07417 </p>   <div class="Figure">    <a name="f06"></a>   <img src="image.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290&name=ond03%2D0009%2D06%2Ejpg" alt="Principal Display Panel – Carton Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ONDANSETRON &nbsp; </strong> <br /> <span class="contentTableReg">ondansetron hydrochloride injection, solution</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:76045-103</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAVENOUS</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Ondansetron Hydrochloride </strong> (UNII: NMH84OZK2B) (Ondansetron - UNII:4AF302ESOS)</td>          <td class="formItem">Ondansetron</td>          <td class="formItem">4&nbsp;mg &nbsp;in&nbsp;2&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Sodium chloride </strong> (UNII: 451W47IQ8X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>Citric Acid Monohydrate </strong> (UNII: 2968PHW8QP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Trisodium citrate Dihydrate </strong> (UNII: B22547B95K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>Water </strong> (UNII: 059QF0KO0R)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:76045-103-20</td>          <td class="formItem">24 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">2.0 mL in 1 SYRINGE, GLASS</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA202253</td>          <td class="formItem">08/23/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>BD Rx Inc. (964475045) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">BD Rx Inc.</td>      <td class="formItem"></td>      <td class="formItem">964475045</td>      <td class="formItem">MANUFACTURE(76045-103) , ANALYSIS(76045-103) , PACK(76045-103) , LABEL(76045-103)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Ondansetron%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=Ondansetron" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=Ondansetron" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00481&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">ONDANSETRON - ondansetron hydrochloride  injection, solution <br></h3>            <h4>Number of versions: 2</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jan 20, 2015</td>                        <td>							                                7                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=163256">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 23, 2013</td>                        <td>							                                6                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=117740">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">ONDANSETRON - ondansetron hydrochloride  injection, solution <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                        <tr>                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1314133">1314133</a></td>                              <td>2 ML Ondansetron 2 MG/ML Prefilled Syringe</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1314133">1314133</a></td>                              <td>ondansetron (as ondansetron hydrochloride) 4 MG per 2 ML Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">ONDANSETRON - ondansetron hydrochloride  injection, solution <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AONDANSETRON%20%2D%20Ondansetron%20Hydrochloride%20Injection%2C%20Solution%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dd89017aa%2Db8c3%2D4fd2%2D8e68%2D44e2cfd6f290%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    